Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer

Peer Review reports

Original Submission
17 Apr 2012	Submitted	Original manuscript
17 May 2012	Reviewed	Reviewer Report - Jonathan Izawa
9 Jun 2012	Reviewed	Reviewer Report - Peter Black
2 Aug 2012	Author responded	Author comments - Nobumichi Tanaka
Resubmission - Version 2
2 Aug 2012	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
Resubmission - Version 4
	Submitted	Manuscript version 4
6 Sep 2012	Author responded	Author comments - Nobumichi Tanaka
Resubmission - Version 5
6 Sep 2012	Submitted	Manuscript version 5
Publishing
11 Sep 2012	Editorially accepted
14 Sep 2012	Article published	10.1186/1471-2490-12-28

Back to article page